Mereo BioPharma Group plc (MREO) Institutional Ownership

Ownership Summary

Mereo BioPharma Group plc (NASDAQ:MREO) appears in 70 institutional 13F filings for the quarter ending December 2025.

• Collectively, these holders controlled 7.8% of Mereo BioPharma's outstanding shares in December 2025, down from 12.7% in September 2025.
• They increased total shares held in Mereo BioPharma by 56.73% from last quarter, and the number of investors in MREO decreased 23.08% annually.
• Of these 70 holders, 37 added to their stakes in Mereo BioPharma, 20 trimmed positions, and 13 made no changes.
• The aggregate institutional position in Mereo BioPharma amounted to 62.18Mn shares as of December 2025, up by 22.51Mn shares quarter on quarter, and down 56.74Mn shares year over year.
• Rubric Capital Management LP holds the largest position in MREO at 15.31Mn shares as of December 31, 2025, or 1.91% of shares outstanding.
• The largest buyers of Mereo BioPharma for the quarter ending December 2025 were 683 Capital Management, LLC (10.15Mn), EcoR1 Capital, LLC (7.86Mn), Schonfeld Strategic Advisors LLC (4.36Mn), Logos Global Management LP (1.35Mn), BALYASNY ASSET MANAGEMENT L.P. (1.28Mn).
• The largest sales of MREO for the quarter ending December 2025 came from Goldman Sachs Group Inc (2.34Mn), Morgan Stanley (2.07Mn), Bank Of America Corp /De/ (851.75K), TWO SIGMA INVESTMENTS, LP (562.97K), RENAISSANCE TECHNOLOGIES LLC (396.5K).
• Per Business Quant data, the top 10 holders of Mereo BioPharma for the quarter ending December 2025 are Rubric Capital Management LP (15.31Mn), 683 Capital Management, LLC (15.02Mn), EcoR1 Capital, LLC (7.86Mn), Schonfeld Strategic Advisors LLC (6.09Mn), Tejara Capital Ltd (2.16Mn), Logos Global Management LP (1.85Mn), UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC (1.76Mn), Monaco Asset Management SAM (1.59Mn), UBS Group AG (1.56Mn), BALYASNY ASSET MANAGEMENT L.P. (1.28Mn).